A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma

BACKGROUND: Flavopiridol, a Cdk inhibitor, potentiates irinotecan-induced apoptosis. In a phase I trial of sequential irinotecan and flavopiridol, 2 patients with advanced hepatocellular carcinoma (HCC) had stable disease (SD) for ≥14 months. We thus studied the sequential combination of irinotecan...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ang, Celina, O'Reilly, Eileen M., Carvajal, Richard D., Capanu, Marinela, Gonen, Mithat, Doyle, Laurence, Ghossein, Ronald, Schwartz, Lawrence, Jacobs, Gria, Ma, Jennifer, Schwartz, Gary K., Abou-Alfa, Ghassan K.
Формат: Artigo
Язык:Inglês
Опубликовано: International Society of Gastrointestinal Oncology 2012
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3533846/
https://ncbi.nlm.nih.gov/pubmed/23293699
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы